Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

HOUSTON, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion and launch of phases one through five of its proprietary virtual clinic and digital research ecosystem. The launch of Nexalin’s virtual clinic took place this week at the University of California, San Diego (UCSD) to support patient recruitment in the recently announced TBI / PTSD military study. This virtual platform will manage the real-time data capture, remote monitoring, and clinical oversight of its HALO™ headset in both research and patient treatment settings. Additionally, this virtual system will allow civilian and military patients to receive treatment in the privacy of their home while the system monitors and validates compliance with clinical research protocols.

Read more at globenewswire.com